Recent events

Shanghai RAAS adjusts second-phase employee stock ownership plan

Shanghai RAAS Blood Products Co., Ltd. (002252) adjusted its second-phase 2026 employee stock ownership plan and disclosed a revised draft, for which Beijing Zhong Lun (Shanghai) Law Firm issued a legal opinion dated October 2026. The revision lowers the planned fundraising cap to 65.4522 million yuan, lowers the planned share scale to up to 23.21 million Shanghai RAAS A-shares sourced from the company's repurchase account, and lowers the expected initial number of participants to no more than 128. Because the company's 2025 annual profit distribution was implemented on June 24, 2026 and the repurchased shares had not yet been transferred to the plan, the purchase price for plan participants was adjusted from 2.85 yuan to 2.82 yuan per share. The revised plan may be financed through asset-management or trust plans funded by financial institutions with a leverage ratio not exceeding 1:1, and may engage external professional institutions to provide asset-management services.